When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ARVN - Arvinas on go with early-stage study of ARV-471 in breast cancer
Arvinas Inc.
The FDA has cleared Arvinas' (NASDAQ:ARVN) IND application for ARV-471, an oral estrogen receptor (ER) PROTAC protein degrader, designed to selectively target ER for the treatment of patients with locally advanced or metastatic ER positive / HER2 negative breast cancer.
More news on: Arvinas, Inc., Healthcare stocks news,